A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|10|1620-1627

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.10, 2015-05, pp. : 1620-1627

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 154-158

Karger

Access to resources Recommend Favorite

Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

By  

Oncology, Vol. 89, Iss. 2, 2015-03 ,pp. : 70-78

Karger

Access to resources Recommend Favorite

Phase II Trial of Navelbine and Fluorouracil as Second-Line Chemotherapy in Metastatic Breast Carcinoma

By  

Oncology, Vol. 55, Iss. 1, 1997-12 ,pp. : 87-88

Karger

Access to resources Recommend Favorite

Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

By  

Oncology, Vol. 85, Iss. 1, 2013-07 ,pp. : 44-52

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite